Understanding remission in real-world lupus patients across five European countries

M. Schneider, M. Mosca, J. M. Pego-Reigosa, E. Hachulla, L. S. Teh, A. Perna, V. Koscielny, J. Pike, Steve Lobosco, G. Apolone

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with increased mortality and significant personal, psychological and socioeconomic consequences. An agreed definition of remission is needed and lacking. We sought to visualize 'remission in SLE' in European patients considered by their physicians to be 'in remission' by comparing the reported symptom burden as reported by treating physicians for patients considered to be 'in remission' and those not considered to be 'in remission'. Data for 1227 patients drawn from a multinational, real-world survey of patients with SLE consulting practising rheumatologists and nephrologists in France, Germany, Italy, Spain, and the UK show that physicians classed their patients as 'in remission' despite a considerable ongoing symptom burden and intensive immunosuppressive medication. Patients considered to be 'in remission' still had a mean of 2.68 current symptoms vs 5.48 for those considered to be not 'in remission' (p <0.0001). The most common symptoms among those seen to be 'in remission' were joint symptoms, fatigue, pain, mucocutaneous involvement, haematological manifestations and kidney abnormalities. The current analysis highlights important ongoing disease activity, symptom burden and immunosuppressive medication in European patients with SLE considered by their treating physician to be 'in remission'. For a further improvement of outcome, there is an urgent need for an international consensus on the definitions for remission among patients with SLE.

Original languageEnglish
Pages (from-to)505-512
Number of pages8
JournalLupus
Volume25
Issue number5
DOIs
Publication statusPublished - Apr 1 2016

Fingerprint

Systemic Lupus Erythematosus
Physicians
Immunosuppressive Agents
Spain
Italy
Autoimmune Diseases
France
Fatigue
Germany
Consensus
Chronic Disease
Joints
Psychology
Kidney
Pain
Mortality

Keywords

  • remission
  • symptom burden
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology

Cite this

Schneider, M., Mosca, M., Pego-Reigosa, J. M., Hachulla, E., Teh, L. S., Perna, A., ... Apolone, G. (2016). Understanding remission in real-world lupus patients across five European countries. Lupus, 25(5), 505-512. https://doi.org/10.1177/0961203315619030

Understanding remission in real-world lupus patients across five European countries. / Schneider, M.; Mosca, M.; Pego-Reigosa, J. M.; Hachulla, E.; Teh, L. S.; Perna, A.; Koscielny, V.; Pike, J.; Lobosco, Steve; Apolone, G.

In: Lupus, Vol. 25, No. 5, 01.04.2016, p. 505-512.

Research output: Contribution to journalArticle

Schneider, M, Mosca, M, Pego-Reigosa, JM, Hachulla, E, Teh, LS, Perna, A, Koscielny, V, Pike, J, Lobosco, S & Apolone, G 2016, 'Understanding remission in real-world lupus patients across five European countries', Lupus, vol. 25, no. 5, pp. 505-512. https://doi.org/10.1177/0961203315619030
Schneider M, Mosca M, Pego-Reigosa JM, Hachulla E, Teh LS, Perna A et al. Understanding remission in real-world lupus patients across five European countries. Lupus. 2016 Apr 1;25(5):505-512. https://doi.org/10.1177/0961203315619030
Schneider, M. ; Mosca, M. ; Pego-Reigosa, J. M. ; Hachulla, E. ; Teh, L. S. ; Perna, A. ; Koscielny, V. ; Pike, J. ; Lobosco, Steve ; Apolone, G. / Understanding remission in real-world lupus patients across five European countries. In: Lupus. 2016 ; Vol. 25, No. 5. pp. 505-512.
@article{dad57b4bfec2461591e0f75a565e4077,
title = "Understanding remission in real-world lupus patients across five European countries",
abstract = "Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with increased mortality and significant personal, psychological and socioeconomic consequences. An agreed definition of remission is needed and lacking. We sought to visualize 'remission in SLE' in European patients considered by their physicians to be 'in remission' by comparing the reported symptom burden as reported by treating physicians for patients considered to be 'in remission' and those not considered to be 'in remission'. Data for 1227 patients drawn from a multinational, real-world survey of patients with SLE consulting practising rheumatologists and nephrologists in France, Germany, Italy, Spain, and the UK show that physicians classed their patients as 'in remission' despite a considerable ongoing symptom burden and intensive immunosuppressive medication. Patients considered to be 'in remission' still had a mean of 2.68 current symptoms vs 5.48 for those considered to be not 'in remission' (p <0.0001). The most common symptoms among those seen to be 'in remission' were joint symptoms, fatigue, pain, mucocutaneous involvement, haematological manifestations and kidney abnormalities. The current analysis highlights important ongoing disease activity, symptom burden and immunosuppressive medication in European patients with SLE considered by their treating physician to be 'in remission'. For a further improvement of outcome, there is an urgent need for an international consensus on the definitions for remission among patients with SLE.",
keywords = "remission, symptom burden, Systemic lupus erythematosus",
author = "M. Schneider and M. Mosca and Pego-Reigosa, {J. M.} and E. Hachulla and Teh, {L. S.} and A. Perna and V. Koscielny and J. Pike and Steve Lobosco and G. Apolone",
year = "2016",
month = "4",
day = "1",
doi = "10.1177/0961203315619030",
language = "English",
volume = "25",
pages = "505--512",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Understanding remission in real-world lupus patients across five European countries

AU - Schneider, M.

AU - Mosca, M.

AU - Pego-Reigosa, J. M.

AU - Hachulla, E.

AU - Teh, L. S.

AU - Perna, A.

AU - Koscielny, V.

AU - Pike, J.

AU - Lobosco, Steve

AU - Apolone, G.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with increased mortality and significant personal, psychological and socioeconomic consequences. An agreed definition of remission is needed and lacking. We sought to visualize 'remission in SLE' in European patients considered by their physicians to be 'in remission' by comparing the reported symptom burden as reported by treating physicians for patients considered to be 'in remission' and those not considered to be 'in remission'. Data for 1227 patients drawn from a multinational, real-world survey of patients with SLE consulting practising rheumatologists and nephrologists in France, Germany, Italy, Spain, and the UK show that physicians classed their patients as 'in remission' despite a considerable ongoing symptom burden and intensive immunosuppressive medication. Patients considered to be 'in remission' still had a mean of 2.68 current symptoms vs 5.48 for those considered to be not 'in remission' (p <0.0001). The most common symptoms among those seen to be 'in remission' were joint symptoms, fatigue, pain, mucocutaneous involvement, haematological manifestations and kidney abnormalities. The current analysis highlights important ongoing disease activity, symptom burden and immunosuppressive medication in European patients with SLE considered by their treating physician to be 'in remission'. For a further improvement of outcome, there is an urgent need for an international consensus on the definitions for remission among patients with SLE.

AB - Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with increased mortality and significant personal, psychological and socioeconomic consequences. An agreed definition of remission is needed and lacking. We sought to visualize 'remission in SLE' in European patients considered by their physicians to be 'in remission' by comparing the reported symptom burden as reported by treating physicians for patients considered to be 'in remission' and those not considered to be 'in remission'. Data for 1227 patients drawn from a multinational, real-world survey of patients with SLE consulting practising rheumatologists and nephrologists in France, Germany, Italy, Spain, and the UK show that physicians classed their patients as 'in remission' despite a considerable ongoing symptom burden and intensive immunosuppressive medication. Patients considered to be 'in remission' still had a mean of 2.68 current symptoms vs 5.48 for those considered to be not 'in remission' (p <0.0001). The most common symptoms among those seen to be 'in remission' were joint symptoms, fatigue, pain, mucocutaneous involvement, haematological manifestations and kidney abnormalities. The current analysis highlights important ongoing disease activity, symptom burden and immunosuppressive medication in European patients with SLE considered by their treating physician to be 'in remission'. For a further improvement of outcome, there is an urgent need for an international consensus on the definitions for remission among patients with SLE.

KW - remission

KW - symptom burden

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=84962592219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962592219&partnerID=8YFLogxK

U2 - 10.1177/0961203315619030

DO - 10.1177/0961203315619030

M3 - Article

AN - SCOPUS:84962592219

VL - 25

SP - 505

EP - 512

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 5

ER -